Medical device company CVRx extends series F financing to $42m, with extra $12m from investors including DaVita HealthCare Partners, in order to advance clinical trials for its system to treat hypertension and heart failure.
CVRx, a medical device company which has developed Barostim neo, a system to treat hypertension and heart failure, has raised an additional $12m under its series F financing from new investors including DaVita HealthCare Partners, a US-based provider of kidney care and healthcare, and Spain-based venture capital firm Ysios Capital.
The funding extension brings the total raised in the series F financing to $42m. Previously, in July 2013, CVRx completed a $29.6m series F financing led by venture capital firm…
